These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 24350936)

  • 1. [Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study].
    Haluzík M; Veselá V; Gerle J; Brada M; Dohnalová L; Edelsberger T; Houdová J
    Vnitr Lek; 2013 Dec; 59(12):1049-56. PubMed ID: 24350936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE).
    Mathieu C; Barnett AH; Brath H; Conget I; de Castro JJ; Göke R; Márquez Rodriguez E; Nilsson PM; Pagkalos E; Penfornis A; Schaper NC; Wangnoo SK; Kothny W; Bader G
    Int J Clin Pract; 2013 Oct; 67(10):947-56. PubMed ID: 23961850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
    Göke R; Gruenberger JB; Bader G; Dworak M
    Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effectivity and security of vildagliptin as additional treatment for Type 2 diabetes mellitus in real-life conditions in Mexico. EDGE Study subanalysis].
    Márquez-Rodríguez E; Brea-Andrea E; Rajmet-Hace VA; Salinas-Salinas J; Mariño-Rojas F
    Gac Med Mex; 2016; 152(4):457-64. PubMed ID: 27595248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.
    Saab C; Al-Saber FA; Haddad J; Jallo MK; Steitieh H; Bader G; Ibrahim M
    Vasc Health Risk Manag; 2015; 11():149-55. PubMed ID: 25750538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
    Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
    J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study.
    Ayvaz G; Keskin L; Akin F; Dokmetas HS; Tasan E; Ar IB; Uren E;
    Curr Med Res Opin; 2015 Apr; 31(4):623-32. PubMed ID: 25697921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
    Bolli G; Dotta F; Colin L; Minic B; Goodman M
    Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
    Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
    Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.
    Younis A; Eskenazi D; Goldkorn R; Leor J; Naftali-Shani N; Fisman EZ; Tenenbaum A; Goldenberg I; Klempfner R
    Cardiovasc Diabetol; 2017 May; 16(1):69. PubMed ID: 28532406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study.
    Prasanna Kumar KM; Phadke U; Brath H; Gawai A; Paldánius PM; Mathieu C
    Prim Care Diabetes; 2016 Dec; 10(6):452-458. PubMed ID: 27353459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
    Filozof C; Gautier JF
    Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Schweizer A; Dejager S; Bosi E
    Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
    Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
    Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin.
    Göke B; Hershon K; Kerr D; Calle Pascual A; Schweizer A; Foley J; Shao Q; Dejager S
    Horm Metab Res; 2008 Dec; 40(12):892-5. PubMed ID: 18726829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
    Li CJ; Yu Q; Yu P; Zhang QM; Ding M; Liu XJ; Yu DM
    Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):469-76. PubMed ID: 24838155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.
    Brath H; Paldánius PM; Bader G; Kolaczynski WM; Nilsson PM
    Nutr Diabetes; 2016 Jul; 6(7):e217. PubMed ID: 27376699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study.
    Ji LN; Pan CY; Lu JM; Li H; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Zhang RY; Wang XL; Wang L;
    Cardiovasc Diabetol; 2013 Aug; 12():118. PubMed ID: 23958390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.